Hematology CME

Tell us what you think about Healio

Sign in for a personal experience.

Customized content served to meet your interests.

Register for Healio to get content tailored to your specialty and areas of interest. It’s FREE and only takes one minute. Register now!

CME
Electro-Gene Therapy with IL-12 Plasmid in Metastatic Melanoma
May 8, 2013
This activity will discuss the safety, efficacy, and side effects of IL-12, as shown in Phase I and Phase II studies… More »
This activity is supported by educational grants from Bristol-Myers Squibb, Delcath Systems, Inc., Merck & Co., Inc., OncoSec Medical, Inc., Prometheus and Provectus Pharmaceuticals, Inc.
Credit Type(s): CME | Credit: 0.25

CME
Debate: “Interferon Sensitivity”: Adjuvant IFN Should Be Used Only in Patients with Ulceration and/or Microscopic Nodal Disease
May 2, 2013
This activity will feature two experts debating the efficacy of high-dose, intermediate-dose and low-dose interferon in melanoma patients in various disease stages and with certain characteristics,… More »
This activity is supported by educational grants from Bristol-Myers Squibb, Delcath Systems, Inc., Merck & Co., Inc., OncoSec Medical, Inc., Prometheus and Provectus Pharmaceuticals, Inc.
Credit Type(s): CME | Credit: 0.5

CME
Does Biochemotherapy Have a Role in Adjuvant Therapy?
May 2, 2013
This activity will discuss the role of biochemotherapy in adjuvant therapy when treating high-risk melanoma patients… More »
This activity is supported by educational grants from Bristol-Myers Squibb, Delcath Systems, Inc., Merck & Co., Inc., OncoSec Medical, Inc., Prometheus and Provectus Pharmaceuticals, Inc.
Credit Type(s): CME | Credit: 0.25

CME
Glioblastoma: Current Perspectives, Clinical Challenges, and Trends in Treatment
July 10, 2012
Glioblastoma is a rare but devastating disease. A variety of treatment modalities are being examined to improve survival in patients with this difficult cancer. Clinicians who treat glioblastoma must… More »
This activity is supported by an educational grant from Merck.
Credit Type(s): CME | Credit: 1.25

Hematology/Oncology